Effects and Tolerance of Silymarin (Milk Thistle) in Chronic Hepatitis C Virus Infection Patients: A Meta-Analysis of Randomized Controlled Trials

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Yang, Zongguo ^a,b   Zhuang, Liping ^c,d   Lu, Yunfei ^a,b   Xu, Qingnian ^a,b   Chen, Xiaorong ^a,b  

^a SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^b Key Laboratory of Infectious Diseases of State Administration of Traditional Chinese Medicine   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PLACEBO; SILIBININ; SILYMARIN; VIRUS RNA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; HEPATITIS C; HUMAN; INFECTION; MEDLINE; META ANALYSIS; MUSCULOSKELETAL PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SILYBUM MARIANUM; WEB OF SCIENCE; CHEMISTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE BASED MEDICINE; HEPATITIS C, CHRONIC; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHYTOTHERAPY; PREVALENCE; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

HEPATITIS C VIRUS; SILYBUM MARIANUM;

ADMINISTRATION, ORAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MILK THISTLE; PHYTOTHERAPY; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SILYMARIN; TREATMENT OUTCOME;

EID: 84930903372     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/941085     Document Type: Review

References (42)

1. D. B. Strader, B. R. Bacon, K. L. Lindsay et al., "Use of complementary and alternative medicine in patients with liver disease," The American Journal of Gastroenterology, vol. 97, no. 9, pp. 2391-2397, 2002.
2. L. B. Seeff, T. M. Curto, G. Szabo et al., "Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial," Hepatology, vol. 47, no. 2, pp. 605-612, 2008.
3. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, "Diagnosis, management, and treatment of hepatitis C: An update," Hepatology, vol. 49, no. 4, pp. 1335-1374, 2009.
4. C. Loguercio and D. Festi, "Silybin and the liver: From basic research to clinical practice,"World Journal of Gastroenterology, vol. 17, no. 18, pp. 2288-2301, 2011.
5. H. S.Althagafy, T.N. Graf, A. A. Sy-Cordero et al., "Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle," Bioorganic and Medicinal Chemistry, vol. 21, no. 13, pp. 3919-3926, 2013.
6. J. Blaising, P. L. Lévy, C. Gondeau et al., "Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrindependent trafficking," Cellular Microbiology, vol. 15, no. 11, pp. 1866-1882, 2013.
7. J. Post-White, E. J. Ladas, and K. M. Kelly, "Advances in the use of milk thistle (Silybum marianum)," Integrative Cancer Therapies, vol. 6, no. 2, pp. 104-109, 2007.
8. A. Pár, E. Roth, A. Miseta et al., "Effects of silymarin supplementation in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study," Orvosi Hetilap, vol. 150, no. 2, pp. 73-79, 2009.
9. A. Gordon, D. A. Hobbs, D. S. Bowden et al., "Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C," Journal of Gastroenterology and Hepatology, vol. 21, no. 1, pp. 275-280, 2006.
10. M.D. Tanamly, F. Tadros, S. Labeeb et al., "Rand omised doubleblinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: Study description and 12-month results," Digestive and Liver Disease, vol. 36, no. 11, pp. 752-759, 2004.
11. M.W. Fried, V. J. Navarro, N. Afdhal et al., "Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A rand omized controlled trial,"The Journal of the AmericanMedical Association, vol. 308, no. 3, pp. 274-282, 2012.
12. Z. Mariño, G. Crespo, M. DAmato et al., "Intravenous silibinin monotherapy shows significant antiviral activity in HCVinfected patients in the peri-transplantation period," Journal of Hepatology, vol. 58, no. 3, pp. 415-420, 2013.
13. P. Ferenci, T. Scherzer, H. Kerschner et al., "Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy," Gastroenterology, vol. 135, no. 5, pp. 1561-1567, 2008.
14. K. Rutter, T. Scherzer, S. Beinhardt et al., "Intravenous silibinin as rescue treatment for on-treatment non-responders to pegylated interferon/ribavirin combination therapy," Antiviral Therapy, vol. 16, no. 8, pp. 1327-1333, 2011.
15. C.Mulrow, V. Lawrence, B. Jacobs et al., "Milk thistle: Effects on liver disease and cirrhosis and clinical adverse effects," Evidence Report/Technology Assessment (Summary), no. 21, pp. 1-3, 2000.
16. B. P. Jacobs, C. Dennehy, G. Ramirez, J. Sapp, and V. A. Lawrence, "Milk thistle for the treatment of liver disease: A systematic review and meta-analysis," The American Journal of Medicine, vol. 113, no. 6, pp. 506-515, 2002.
17. R. Saller, R.Meier, and R. Brignoli, "The use of silymarin in the treatment of liver diseases," Drugs, vol. 61,no. 14,pp. 2035-2063, 2001.
18. A. Rambaldi, B. P. Jacobs, and C. Gluud, "Milk thistle for alcoholic and /or hepatitis B or C virus liver diseases," Cochrane Database of Systematic Reviews, vol. 17, no. 4, 2007.
19. J. P. T. Higgins and S. Green, Eds., Cochrane Hand book for Systematic Reviews of Interventions,Version 5.1.0,TheCochrane Collaboration, 2011, http://hand book.cochrane.org/.
20. J. Luo and W. D. Leng, Theory & Practice of Systematic Review/Meta-Analysis, Military Medical Science Press, 2013.
21. J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in ameta-analysis," Statistics in Medicine, vol. 21,no. 11,pp. 1539-1558, 2002.
22. O. Adeyemo, H. Doi, K. R. Reddy, and D. E. Kaplan, "Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection," Journal of Viral Hepatitis, vol. 20, no. 7, pp. 453-462, 2013.
23. S. J. Schrieber, R. L. Hawke, Z. Wen, P. C. Smith, K. R. Reddy, and A. S. Wahed, "Differences in the disposition of patients with nonalcoholic fatty liver disease and chronichepatitis," Drug Metabolism and Disposition, vol. 39, no. 12, pp. 2182-2190, 2011.
24. A. El-Zayadi, M. Attia, H. M. Badran et al., "Non-interferonbased therapy: An option for amelioration of necroinflammation in hepatitis C patients who cannot afford interferon therapy," Liver International, vol. 25, no. 4, pp. 746-751, 2005.
25. M. Yakoot and A. Salem, "Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot rand omized, comparative clinical trial," BMC Gastroenterology, vol. 12, article 32, 2012.
26. R. L. Hawke, S. J. Schrieber, T. A. Soule et al., "Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C," The Journal of Clinical Pharmacology, vol. 50, no. 4, pp. 434-449, 2010.
27. K. R. Reddy, S. H. Belle, M. W. Fried et al., "Rationale, challenges, and participants in a phase II trial of a botanical product for chronic hepatitis C," Clinical Trials, vol. 9, no. 1, pp. 102-112, 2012.
28. J. M. Bares, J. Berger, J. E. Nelson et al., "Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitisC," Journal of ClinicalGastroenterology, vol. 42, no. 8, pp. 937-944, 2008.
29. N. Hayashi and T. Takehara, "Antiviral therapy for chronic hepatitis C: Past, present, and future," Journal of Gastroenterology, vol. 41, no. 1, pp. 17-27, 2006.
30. European Association for the Study of the Liver, "EASL clinical practice guidelines: Management of hepatitis C virus infection," Journal of Hepatology, vol. 2, pp. 245-264, 2011.
31. M. G. Ghany,D. R. Nelson, D. B. Strader, D. L. Thomas, and L. B. Seeff, "An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases," Hepatology, vol. 54, no. 4, pp. 1433-1444, 2011.
32. R. Agarwal, C. Agarwal, H. Ichikawa, R. P. Singh, and B. B. Aggarwal, "Anticancerpotential of silymarin: Frombench tobed side," Anticancer Research B, vol. 26, no. 6, pp. 4457-4498, 2006.
33. B. Ahmed, S. A. Khan, and T. Alam, "Synthesis and antihepatotoxic activity of some heterocyclic compounds containing the 1,4-dioxane ring system," Pharmazie, vol. 58, no. 3, pp. 173-176, 2003.
34. N. D. Freedman, T. M. Curto, C. Morishima et al., "Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial," Alimentary Pharmacology and Therapeutics, vol. 33, no. 1, pp. 127-137, 2011.
35. J. Wagoner, A. Negash, O. J. Kane et al., "Multiple effects of silymarin on the hepatitis C virus lifecycle," Hepatology, vol. 51, no. 6, pp. 1912-1921, 2010.
36. J. Wagoner, C. Morishima, T. N. Graf et al., "Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation," PLoS ONE, vol. 6, no. 1, Article ID e16464, 2011.
37. A. Ahmed-Belkacem, N. Ahnou, L. Barbotte et al., "Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase," Gastroenterology, vol. 138, no. 3, pp. 1112-1122, 2010.
38. J. Guedj, H. Dahari, R. T. Pohl, P. Ferenci, and A. S. Perelson, "Understand ing silibinins modes of action against HCV using viral kinetic modeling," Journal of Hepatology, vol. 56, no. 5, pp. 1019-1024, 2012.
39. B. Sengupta, A. Banerjee, and P. K. Sengupta, "Investigations on the binding and antioxidant properties of the plant flavonoid fisetin in model biomembranes," FEBS Letters, vol. 570, no. 1-3, pp. 77-81, 2004.
40. P. A. L. Bonis, J. P. A. Ioannidis, J. C. Cappelleri, M. M. Kaplan, and J. Lau, "Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A metaanalysis of diagnostic test characteristics," Hepatology, vol. 26, no. 4, pp. 1035-1044, 1997.
41. M. L. Shiffman, C. M. Hofmann, E. B. Thompson et al., "Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C," Hepatology, vol. 26, no. 3, pp. 780-785, 1997.
42. J. Zarski, B. Bohn, A. Bastie et al., "Characteristics of patients with dual infection by hepatitis B and C viruses," Journal of Hepatology, vol. 28, no. 1, pp. 27-33, 1998.